Literature DB >> 6291455

Rifampin inhibition of the occluded virus form of a nuclear polyhedrosis virus.

E M Dougherty, R M Weiner, J L Vaughn, C F Reichelderfer.   

Abstract

Rifampin at concentrations toxic to noninfected cells but not to infected cells is a selective inhibitor of occluded virus of the group A Baculoviridae (nuclear polyhedrosis virus). However, the titer of nonoccluded virus is not affected. Rifampin blocks occlusion until late in the replication cycle (14 to 16 h), and its effects are reversible. Modes of action of polyhedral inclusion body production are unknown.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6291455      PMCID： PMC183780          DOI： 10.1128/AAC.22.3.527

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Physical Factors That Affect In Vitro Autographa californica Nuclear Polyhedrosis Virus Infection.

Authors:  E M Dougherty; R M Weiner; J L Vaughn; C F Reichelderfer
Journal:  Appl Environ Microbiol       Date:  1981-05       Impact factor: 4.792

2.  Vaccinia as a model for membrane biogenesis.

Authors:  S Dales; E H Mosbach
Journal:  Virology       Date:  1968-08       Impact factor: 3.616

3.  Isolation, Complementation, and Initial Characterization of Temperature-Sensitive Mutants of the Baculovirus Autographa californica Nuclear Polyhedrosis Virus.

Authors:  H H Lee; L K Miller
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

4.  Genetic Analysis of a Baculovirus, Autographa californica Nuclear Polyhedrosis Virus I. Isolation of Temperature-Sensitive Mutants and Assortment into Complementation Groups.

Authors:  M Brown; A M Crawford; P Faulkner
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

5.  Interruption by Rifampin of an early stage in vaccinia virus morphogenesis: accumulation of membranes which are precursors of virus envelopes.

Authors:  P M Grimley; E N Rosenblum; S J Mims; B Moss
Journal:  J Virol       Date:  1970-10       Impact factor: 5.103
  5 in total
  1 in total

Review 1.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.